TY - JOUR
T1 - Anti-SARS-CoV-2 vaccination in people with multiple sclerosis
T2 - Lessons learnt a year in
AU - Pugliatti, Maura
AU - Hartung, Hans-Peter
AU - Oreja-Guevara, Celia
AU - Pozzilli, Carlo
AU - Airas, Laura
AU - Alkhawajah, Mona
AU - Grigoriadis, Nikolaos
AU - Magyari, Melinda
AU - Van Wijmeersch, Bart
AU - Zakaria, Magd
AU - Linker, Ralf
AU - Chan, Andrew
AU - Vermersch, Patrick
AU - Berger, Thomas
N1 - Copyright © 2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger.
PY - 2022
Y1 - 2022
N2 - It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
AB - It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
KW - Humans
KW - SARS-CoV-2
KW - COVID-19/prevention & control
KW - Multiple Sclerosis
KW - COVID-19 Vaccines
KW - Vaccination
UR - https://www.scopus.com/pages/publications/85140995489
U2 - 10.3389/fimmu.2022.1045101
DO - 10.3389/fimmu.2022.1045101
M3 - Review
C2 - 36325318
SN - 1664-3224
VL - 13
SP - 1
EP - 8
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1045101
ER -